

## The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)

### Abstract

**Background:** Considering the effect of statins on the regulation of dopamine neurotransmitters and glutamates and importance of the treatment of obsessive-compulsive disorder (OCD) due to its relatively high prevalence and disability of available drugs in treatment of many patients, we came to the point to examine effectiveness of statins in patients with OCD. **Materials and Methods:** This study is a double-blind randomized clinical trial, which is done in OCD clinic of Isfahan Shariati in 2014 for 1 year. The target population consists of 64 patients with OCD; one group is given a daily 40 mg atorvastatin tablets and the other group receives placebo. At baseline, 4- and 8-week severities of obsessive-compulsive symptoms are measured using Yale–Brown scale and compared in the two groups. **Results:** The study results show a statistically significant difference between the two groups of intervention and control ( $P < 0.001$ ). Furthermore, the results show the intervention effect at the end of the 4<sup>th</sup> week and 8<sup>th</sup> week ( $P < 0.001$ ) that this change is evident in the 4<sup>th</sup> week but remained almost constant in the 8<sup>th</sup> week. **Conclusion:** Overall, the evidences obtained from the study declare the effects of adding statins to treat obsessive-compulsive symptoms.

**Keywords:** Add-on therapy, atorvastatin, obsessive-compulsive disorder, refractory obsessive-compulsive disorder

### Introduction

Obsessive-compulsive disorder (OCD) has a prevalence of 2–3% of the general population and in patients referred to psychiatry clinics up to 10%.<sup>[1]</sup> OCD symptoms are very versatile and range from penetrating thoughts and obsessive preoccupation to the obsessive practices and customs.<sup>[2]</sup> Although 5-hydroxytryptamine (5-HT) is still known as major neurotransmitter involved in OCD symptoms, 5-HT abnormalities may be the result of OCD rather than the cause of it.<sup>[3]</sup> Among the treatments based on numerous published trials and according to several meta-analyses and practical guides, selective serotonin reuptake inhibitors (SSRIs) and clomipramine, which is also a serotonin reuptake inhibitor, are introduced as first-line treatment for OCD.<sup>[4–9]</sup>

The results from clinical and preclinical trials suggest that the dopamine system may be involved in the pathogenesis of OCD,<sup>[10]</sup> and it is proposed as the reduction of phase 1 in stimulation of D1 receptor in

obsessive patients.<sup>[11]</sup> Despite the limited number of studies, the results of further research imply a link between OCD and increase of dopamine neurotransmission in the brain, and the hypothesis of an increase in dopamine neurotransmitter in the basal ganglia is agreed.<sup>[12]</sup> Furthermore, growing evidence supports the role of basal ganglia dopaminergic neurotransmission and midbrain that decrease the ability of frontal cortex to suppress emotional responses made in the amygdale.<sup>[10]</sup> Another neurotransmitter involved in the etiology of OCD is glutamate. In recent years, several lines of evidence have emphasized glutamatergic dysfunction in brain's corticostriatal thalamic-cortical circuitry in the etiology of OCD.<sup>[13]</sup> The importance of glutamate in the pathophysiology of OCD is proven and that causes the use of effective drugs on glutamatergic system in addition to the serotonergic drugs.<sup>[14,15]</sup> That's why the glutamatergic factors are new candidates in the treatment of OCD.<sup>[15,16]</sup>

Studies have shown that about 40% of patients with OCD do not respond to

Shahla Akouchekian, Victoria Omranifard<sup>1</sup>, Parivash Moshfegh<sup>2</sup>, Mohammad Reza Maracy<sup>3</sup>, Asiyeh Almasi

From the Behavioral Sciences Research Center, Isfahan University of Medical Sciences, <sup>1</sup>Psychosomatic Research Center, Isfahan University of Medical Sciences, <sup>2</sup>Department of Psychiatry, Medical School, University of Medical Sciences, <sup>3</sup>Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

*Address for correspondence:*  
Dr. Parivash Moshfegh,  
Medical School, Isfahan  
University of Medical Sciences,  
Isfahan, Iran.  
E-mail: [parivash.moshfegh@yahoo.com](mailto:parivash.moshfegh@yahoo.com)

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Akouchekian S, Omranifard V, Moshfegh P, Maracy MR, Almasi A. The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy). *Adv Biomed Res* 2018;7:90.

**Received:** October, 2016. **Accepted:** February, 2017.

#### Access this article online

**Website:** [www.advbiores.net](http://www.advbiores.net)

**DOI:** 10.4103/abr.abr\_114\_16

#### Quick Response Code:



SSRI.<sup>[17,18]</sup> Search for second-line treatment strategies is clinically important in patients with OCD because patients with OCD are less responsive to treatment than other anxiety disorders, and probability of spontaneous recovery is low in OCD; therefore, there is a need for effective drug treatments to reduce long-term disability in such patients.<sup>[19,20]</sup>

Statins are drugs that their main function is to lower cholesterol and have anti-inflammatory and neuroprotective effects.<sup>[21]</sup> Several studies indicate statins' regulatory role on neurotransmitter dopamine in the striatum and its decrease in the prefrontal cortex.<sup>[21]</sup> Another study shows that simvastatin increases dopamine receptors in the prefrontal cortex of rats. High doses of simvastatin cause upregulation in D1 and D2 receptors expression in the prefrontal cortex with potential mechanisms of endothelial nitric oxide synthase. The results of this study suggest that statins can alter dopaminergic activity by probable central mechanism.<sup>[22]</sup> Studies have shown that statins are effective in regulating neurotransmitter glutamate. In one study, simvastatin reduced anxiety-like activity by maintaining the receptor expressions of N-methyl-D-aspartate (NMDA) in an experimental model of parkinsonism. NMDA receptor regulation by simvastatin partly explains the anxiolytic activity and its anti-inflammatory mechanisms in experimental models of parkinsonism. This study shows that statins can prevent neuronal degeneration of dopamine in experimental models of parkinsonism.<sup>[23]</sup>

High doses of simvastatin cause upregulation in NMDA receptors in different areas of the brain and can have hyperlocomotive and anxiolytic effects. Simvastatin plays an important role in the regulation of psycho-degenerative disorders by affecting NMDA receptors.<sup>[23]</sup> Although there were no particular clinical trials regarding the effectiveness of statins in obsession and given the importance of treating the OCD symptoms or attention to the positive effects of statins in preserving the function of brain neurons as well as the brain neurotransmitters and also the mechanisms of their effectiveness in other inflammatory based disorders and considering the safety of statins and no major negative effects, doing clinical trials to evaluate their effectiveness in OCD has a reasonable justification.

## Materials and Methods

### Study design and participants

The present study is a double-blind clinical trial, which assessed psychologist without the knowledge of the people are in which group evaluated the patients, patients without knowing which group they are in, were delivered their medication from the drug delivery person, in the meantime, delivery drug did not have aware about drugs (which one is drug and which one is placebo). IRCT2016041527392 and ethical university code 293116.

$$n = \frac{2(Z_1)^2 S^2}{d^2}, \quad Z_1: \text{Confidence coefficient} = 0.095 \text{ it means } 1.96, \quad d: \text{sampling error} = 2 \text{ (minimum of OCD}$$

mean differences between two groups that reject zero hypothesis), and s: Maximum standard deviation (SD) for obsession = 1/6.

Using sample size formula, 64 patients with refractory OCD referring to obsession clinic of Shariati Isfahan in 2014 for 1 year are selected, regarding inclusion and exclusion criteria. They are randomly categorized into two groups (intervention and placebo). The study group of 64 patients with refractory OCD who are treated for at least 12 weeks with SSRI or clomipramine with the maximum tolerated dose and psychotherapy, and their scores on the scale of Yale–Brown are more than 16.<sup>[24]</sup>

Inclusion criteria include the presence of OCD criteria according to Diagnostic and Statistical Manual of Mental Disorders, 4<sup>th</sup> Edition, Text Revision, receipt of serotonergic drugs (SSRI or clomipramine) at least 12 weeks at the maximum tolerated dose, moderate to severe symptoms based on Yale–Brown Obsessive Compulsive Scale (Y-BOCS) score >16 [Figure 1], obtaining informed consent from patients, aged between 18 and 50 years, absence of mental retardation and disability, absence of serious medical conditions (chronic heart disease, lung disease, and diabetes), substance abuse, and pregnancy. Exclusion criteria include hypersensitivity to statins, high liver enzymes, refusal to complete the study, and planned pregnancy during the study. Sampling is random, and patients with inclusion criteria are in Group 1 (drugs) and Group 2 (placebo). Patients are divided into two groups according to the table of random numbers; raters, researchers and patients are not aware of the division of patients into the case and placebo groups. First, for ethical violations, investigators explain the steps, purpose, and duration to the participants, and consent forms are filled.

For intervention group, 20 mg atorvastatin is started a day till 1 month after the 1<sup>st</sup> month, based on patient's tolerance, the dose is increased 10 mg till it reaches 40 mg/day. The dose is determined on the basis of administration of

| Y-BOCS TOTAL(add items 1-10)  |                          | Date                     | Day                      | Mth.                     | Year                     | Kater |
|---|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------|
| Patient Name  |                          | Patient id               |                          |                          |                          |       |
| Obsessions  | None                     | Mild                     | Moderate                 | Severe                   | Extreme                  |       |
|   | 0                        | 1                        | 2                        | 3                        | 4                        |       |
| 1 TIME SPENT ON OBSESSIONS<br>1b Obsession-free interval<br>(do not add to subtotal or total score)   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 2 INTERFERENCE FROM OBSESSIONS  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 3 DISTRESS OF OBSESSIONS  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 4 RESISTANCE  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 5 CONTROL OVER OBSESSIONS   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| <b>OBSESSION SUBTOTAL(add items 1-5)</b>  |                          |                          |                          |                          |                          |       |
| Compulsions   | None                     | Mild                     | Moderate                 | Severe                   | Extreme                  |       |
|   | 0                        | 1                        | 2                        | 3                        | 4                        |       |
| 6 TIME SPENT ON COMPULSIONS<br>6a Compulsion-free interval<br>(do not add to subtotal or total score) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 7 INTERFERENCE FROM COMPULSION  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 8 DISTRESS FROM COMPULSIONS   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 9 RESISTANCE  | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| 10 CONTROL OVER COMPULSIONS   | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |       |
| <b>COMPULSION SUBTOTAL(add items 6-10)</b>  |                          |                          |                          |                          |                          |       |

Figure 1. Yale–Brown Obsessive Compulsive Scale (Y-BOCS)

atorvastatin in patients with hypercholesterolemia.<sup>[14]</sup> The Group 2 receives placebo pills. In both groups, the previous dose of SSRI drugs or clomipramine that patients used to receive is maintained. Again, by the same psychologist, Y-BOCS is completed at the end of week 4 and 8.

A checklist of the effects of atorvastatin is prepared by the investigators, which includes the most common side effects of statins, headache, abdominal pain, and constipation. Another complication is myopathy and myalgia which happens in utmost 10% of consumers. An increase of liver enzymes in 1%–1.5% of patients who consume statins can be seen that if aspartate aminotransferase  $\geq 3$  goes up, atorvastatin is discontinued and otherwise it is continued. Initially, seventy patients enrolled in the study which three of them were excluded from the study after 1<sup>st</sup> month of using drug, due to drug reactions and not willing to continue. Three patients in placebo group left the study. Finally, 32 patients in each group complete the study. The researchers at all stages are committed to the provisions of the Code of Ethics and Ethics Committee of the Ministry of Health, Isfahan University of Medical Sciences. Written consent is taken from patients.

Collected data are analyzed by computer using SPSS software version 22 (SPSS Inc. Chicago, ILL) and statistical tests such as Friedman test and Mann–Whitney U-test for difference between groups (intervention and placebo). Friedman test used for follow-up time (trend of outcome while intervention). Normality of outcome has been checked by Shapiro–Wilk test.  $P < 0.05$  is considered meaningful.

## Results

In this project, 64 patients with OCD selected with age average 18–50. The majority of patients was women and divided into two groups randomly (intervention and placebo).

Shapiro–Wilk test showed that the OCD score was not normality distribution; because of this reason, we used nonparametric tests such as Friedman test and Mann–Whitney U-test.

The data showed the mean age of 36.2 and SD of 10.4 in the intervention group and mean age of 33.85 and SD of 9.8 in placebo group that 85% of them are female. More details are given in Table 1.

As shown in Table 1, Friedman test in both groups shows (intervention and placebo) a significant different during 8 weeks ( $P < 0.001$ ).

From Table 2, data has shown that Y-BOCS score in baseline and the 4<sup>th</sup> week is significant and reduce in both groups ( $P < 0.027$ ) as well as the difference between 4<sup>th</sup> week and 8<sup>th</sup> week ( $P < 0.091$ ), but this reduction in treatment group is more than placebo group, whereas there is not significantly reduction between baseline and 8<sup>th</sup> weeks in both groups ( $P > 0.219$ ).

**Table 1: Mean and standard deviation and Friedman test, Yale-Brown score before the intervention, the 4<sup>th</sup> and 8<sup>th</sup> weeks of intervention and placebo groups**

| Variable           | <i>n</i> | Mean (SD)    | <i>P</i> * |
|--------------------|----------|--------------|------------|
| Intervention group |          |              |            |
| Baseline           | 33       | 22.24 (5.02) | <0.001     |
| After 4 weeks      | 30       | 16.86 (5.88) |            |
| After 8 weeks      | 29       | 16.27 (7.31) |            |
| Placebo group      |          |              |            |
| Baseline           | 30       | 23.56 (6.22) | <0.001     |
| After 4 weeks      | 27       | 21.25 (8.33) |            |
| After 8 weeks      | 26       | 18.88 (8.81) |            |

\*Friedman test. SD: Standard deviation

## Discussion

The aim of this study was to evaluate the efficacy of adding atorvastatin to the treatment of patients with refractory OCD.

Data show that Y-BOCS score in baseline and the 4<sup>th</sup> week is significant reduce in both groups ( $P < 0.027$ ) and difference between 4<sup>th</sup> week and 8<sup>th</sup> week ( $P < 0.091$ ), but this reduction in treatment group is more than placebo group, whereas there is not significantly reduction between baseline and 8<sup>th</sup> weeks in both groups ( $P > 0.219$ ). Overall, the evidence obtained from the study represents the effects of adding statins to treat obsessive-compulsive symptoms.

Atorvastatin works by reducing the production of low-density lipoprotein (LDL) cholesterol by the liver. This has a knock-on effect of making the liver cells that take up LDL cholesterol from the blood. Atorvastatin also causes a small decrease in the production of other “bad fats” in the blood called triglycerides and a small increase in the level of high-density lipoprotein cholesterol. The overall result is lowered levels of “bad fats” and raised levels of “good fats” in the blood. Statins such as atorvastatin have an important role in the prevention of coronary heart disease and stroke because they reduce the risk of excess cholesterol being deposited in the major blood vessels of the heart and brain. Any blockage in these blood vessels limits the amount of blood and therefore oxygen that can be carried to the heart or brain. In the heart, this can cause chest pain (angina) and in severe cases can result in a heart attack (myocardial infarction), while in the brain, it can cause a stroke. Atorvastatin slows down hardening of the arteries, regardless of your initial cholesterol level. It reduces the risk of needing procedures to improve blood supply to the heart, such as a balloon dilation of an artery or a heart bypass graft. It also reduces the risk of heart attack, stroke, and death from heart disease.<sup>[21]</sup>

According to some studies, anti-inflammatory effects and neuroprotective of statins on preserving the function of neurotransmitters in the pathogenesis of OCD are confirmed.<sup>[20,25–29]</sup>

**Table 2: Mann-Whitney test of the impact of intervention on obsessive-compulsive disorder symptoms in baseline, the end of the 4<sup>th</sup> week, and 8<sup>th</sup> weeks**

| Variant  | Treatment group |        | Placebo group |        | P*    |
|--|-----------------|--------|---------------|--------|-------|
|  | Mean (SD)       | Median | Mean (SD)     | Median |       |
| Difference between baseline and 4 <sup>th</sup> week             | 5.37 (5.5)      | 6      | 2.32 (5.5)    | 0      | 0.027 |
| Difference between baseline and 8 <sup>th</sup> week             | 5.96 (7.28)     | 8      | 4.68 (6.05)   | 3      | 0.219 |
| Difference between 4 <sup>th</sup> week and 8 <sup>th</sup> week | 0.59 (4.63)     | 0      | 2.26 (3.4)    | 2.3    | 0.091 |

\*Mann-Whitney test. SD: Standard deviation

One of these effective neurotransmitters is dopaminergic system.<sup>[10]</sup> For this reason, in OCD patients, dopamine antagonists are suitable for augmentation.<sup>[30]</sup> Statins regulate neurotransmitter dopamine in the striatum and decrease dopamine in the prefrontal cortex.<sup>[22]</sup>

The mechanism of action of statins in OCD may be due to their pharmacological effects on 5-HT transporters and norepinephrine transporters in addition to dopamine.<sup>[30]</sup> On the other hand, glutamate is involved in the pathophysiology of OCD,<sup>[19,20]</sup> and it is found that statins are effective in the regulation of glutamate neurotransmitter.<sup>[23]</sup>

Among other immunological involvement in OCD is the increasing prevalence of OCD in patients with rheumatic fever and an increase in OCD-related disorders among relatives of patients with rheumatic fever. Tumor necrosis factor alpha (TNF- $\alpha$ ) is an inflammatory cytokine in rheumatic fever and autoimmune disease. TNF- $\alpha$  polymorphism is associated with rheumatic fever, considering connection between rheumatic fever and OCD, the relation between OCD and TNF arises.<sup>[31]</sup> Previous studies have also shown that there is a close relationship between OCD and Tourette syndrome. Half of the patients with Tourette disorder have OCD criteria, and <10% of patients with OCD have Tourette syndrome criteria.<sup>[32]</sup>

In a study, it was shown that interleukin (IL)-12 and TNF concentration is increased in Tourette patients, and both of these markers increase in the later periods of exacerbation of symptoms. This study showed that exacerbation of symptoms associated with an inflammatory process is happened due synthesis of local and systemic cytokines that may affect the central nervous system.<sup>[33]</sup>

In a study of cytokines in Tourette disorder in children and adolescents, only those patients who had OCD at the same time showed significantly increased levels of IL-12. In this group, IL-2 was significantly higher than other groups. This study indicated that OCD associated with Tourette disorder is effective on cytokine profile.<sup>[34]</sup> Statins reduce the secretion of IL-6 caused by lipopolysaccharide.<sup>[35]</sup> Statins are related with inflammatory cytokines, and patients with statin treatment have lower C-reactive protein levels.<sup>[36]</sup> In a study, it is reported that statins exert their anti-inflammatory effects in endothelium and leukocytes through downregulation cytokines. In this study, reduction of IL-6 and IL-8 followed by statin therapy is observed.<sup>[37]</sup> The above evidence indicates that statins can reduce the

symptoms of OCD through the reduction of inflammatory factors. Statins can also cause oxidative stress reduction. In another study, statins reduced oxidative stress in patients with chronic obstructive pulmonary disease and ischemic heart disease.<sup>[38,39]</sup> Therefore, statins can stop pathophysiology of oxidative stress causing OCD.

## Conclusion

All the above evidence suggests that statins can reduce OCD symptoms by various mechanisms. Hence, these drugs can be considered as adjuvant in the treatment of obsessive-compulsive disorder.

## Acknowledgments

We wish to thank Psychosomatic Research Center of Isfahan University of Medical Sciences who supported this work and also all staffs of IUMS who participated in our study.

## Financial support and sponsorship

This work was supported by Psychosomatic Research Center of Isfahan University of Medical Sciences.

## Conflicts of interest

There are no conflicts of interest.

## References

1. Pyati S, Gan TJ. Perioperative pain management. *CNS Drugs* 2007;21:185-211.
2. Gramke HF, de Rijke JM, van Kleef M, Raps F, Kessels AG, Peters ML, *et al.* The prevalence of postoperative pain in a cross-sectional group of patients after day-case surgery in a university hospital. *Clin J Pain* 2007;23:543-8.
3. Mixer CG 3<sup>rd</sup>, Meeker LD, Gavin TJ. Preemptive pain control in patients having laparoscopic hernia repair: A comparison of ketorolac and ibuprofen. *Arch Surg* 1998;133:432-7.
4. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, *et al.* Opioid complications and side effects. *Pain Physician* 2008;11 2 Suppl: S105-20.
5. Hopf HW, Weitz S. Postoperative pain management. *Archives of Surgery*. 1994 ;129(2):128-33.
6. Sun Y, Gan TJ, Dubose JW, Habib AS. Acupuncture and related techniques for postoperative pain: A systematic review of randomized controlled trials. *Br J Anaesth* 2008;101:151-60.
7. Sahmeddini MA, Farbood A, Ghafaripour S. Electro-acupuncture for pain relief after nasal septoplasty: A randomized controlled study. *J Altern Complement Med* 2010;16:53-7.
8. Karaman S, Kocabas S, Zincircioglu C, Firat V. Has ketamine preemptive analgesic effect in patients undergoing abdominal

- hysterectomy? *Agri* 2006;18:36-44.
9. Beehrle DM, Evans D. A review of NSAID complications: gastrointestinal and more. *Lippincotts Prim Care Pract* 1999;3(3):305-15.
  10. Denys D, Zohar J, Westenberg HG. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. *J Clin Psychiatry* 2004;65 Suppl 14:11-7.
  11. Joel D, Doljansky J. Selective alleviation of compulsive lever-pressing in rats by D1, but not D2, blockade: Possible implications for the involvement of D1 receptors in obsessive-compulsive disorder. *Neuropsychopharmacology* 2003;28:77-85.
  12. Westenberg HG, Fineberg NA, Denys D. Neurobiology of obsessive compulsive disorder: Serotonin and beyond. *CNS Spectr* 2007;12 2 Suppl 3:14-27.
  13. Ting JT, Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. *Curr Chem Genomics* 2008;2:62-75.
  14. Harsányi A, Csigó K, Demeter G, Németh A. New approach to obsessive-compulsive disorder: dopaminergic theories. *Psychiatr Hung* 2007;22:248-58.
  15. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. *NeuroRx* 2006;3:69-81.
  16. Bhattacharyya S, Chakraborty K. Glutamatergic dysfunction – Newer targets for anti-obsessional drugs. *Recent Pat CNS Drug Discov* 2007;2:47-55.
  17. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. *Psychiatr Clin North Am* 2006;29:553-84, xi.
  18. Stein DJ, Ipser JC, Baldwin DS, Bandelow B. Treatment of obsessive-compulsive disorder. *CNS Spectr* 2007;12 Suppl 3:S28-835.
  19. Huppert JD, Schultz LT, Foa EB, Barlow DH, Davidson JR, Gorman JM, *et al.* Differential response to placebo among patients with social phobia, panic disorder, and obsessive-compulsive disorder. *Am J Psychiatry* 2004;161:1485-7.
  20. Bland RC, Newman SC, Orn H. Age and remission of psychiatric disorders. *Can J Psychiatry* 1997;42:722-9.
  21. Wang G, Ting WL, Yang H, Wong PT. High doses of simvastatin up-regulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: Possible involvement of endothelial nitric oxide synthase col. *Br J Pharmacol* 2005;144:933-9.
  22. Wang Q, Tang XN, Wang L, Yenari MA, Ying W, Goh BC, *et al.* Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats. *Neurosci Lett* 2006;408:189-93.
  23. Wang Q, Zengin A, Deng C, Li Y, Newell KA, Yang GY, *et al.* High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: The association with the up-regulation of NMDA receptor binding in the rat brain. *Exp Neurol* 2009;216:132-8.
  24. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive compulsive disorder: Current strategies. *J Clin Psychiatry* 1994;55 Suppl 3:11-7.
  25. Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, Wongkajornsilp A, Barnes PJ. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. *J Allergy Clin Immunol* 2010;126:754-62.e1.
  26. Kudaravalli J. Improvement in endothelial dysfunction in patients with systemic lupus erythematosus with N-acetylcysteine and atorvastatin. *Indian J Pharmacol* 2011;43:311-5.
  27. Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H, Frederiksen J. Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. *Cardiovasc Res* 2006;72:438-46.
  28. Tsakiri A, Kallenbach K, Fuglø D, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: A randomized study. *Mult Scler* 2012;18:72-81.
  29. Farsaei S, Khalili H, Farboud ES. Potential role of statins on wound healing: Review of the literature. *Int Wound J* 2012;9:238-47.
  30. Denys D, Fineberg N, Carey PD, Stein DJ. Quetiapine addition in obsessive-compulsive disorder: Is treatment outcome affected by type and dose of serotonin reuptake inhibitors? *Biol Psychiatry* 2007;61:412-4.
  31. Hounie AG, Cappi C, Cordeiro Q, Sampaio AS, Moraes I, Rosário MC, *et al.* TNF-alpha polymorphisms are associated with obsessive-compulsive disorder. *Neurosci Lett* 2008;442:86-90.
  32. Brynska A, Wolanczyk T. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). A report of two cases. *Psychiatr Pol* 2004;38:105-23.
  33. Leckman JF, Katsovich L, Kawikova I, Lin H, Zhang H, Krönig H, *et al.* Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. *Biol Psychiatry* 2005;57:667-73.
  34. Gabbay V, Coffey BJ, Guttman LE, Gottlieb L, Katz Y, Babb JS, *et al.* A cytokine study in children and adolescents with Tourette's disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33:967-71.
  35. Bellosa S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. *Ann Med* 2000;32:164-76.
  36. Lyngdoh T, Vollenweider P, Waeber G, Marques-Vidal P. Association of statins with inflammatory cytokines: A population-based Colaus study. *Atherosclerosis* 2011;219:253-8.
  37. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, *et al.* Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. *Arterioscler Thromb Vasc Biol* 2002;22:1194-9.
  38. Kaya C, Pabuccu R, Cengiz SD, Dunder I. Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. *Exp Clin Endocrinol Diabetes* 2010;118:161-6.
  39. Li J, Sun YM, Wang LF, Li ZQ, Pan W, Cao HY. Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. *Clin Cardiol* 2010;33:222-7.